Vaccine-elicited CD8+T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice

Sujin Lee, Kate L. Stokes, Michael G. Currier, Kaori Sakamoto, Nicholas W. Lukacs, Esteban Celis, Martin L. Moore

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

CD8+ T cells may contribute to vaccines for respiratory syncytial virus (RSV). Compared to CD8+ T cells responding to RSV infection, vaccine-elicited anti-RSV CD8+ T cells are less well defined. We used a peptide vaccine to test the hypothesis that vaccine-elicited RSV-specific CD8+ T cells are protective against RSV pathogenesis. BALB/c mice were treated with a mixture (previously termed TriVax) of an M282-90 peptide representing an immunodominant CD8 epitope, the Toll-like receptor (TLR) agonist poly(I·C), and a costimulatory anti-CD40 antibody. TriVax vaccination induced potent effector anti-RSV CD8+ cytotoxic T lymphocytes (CTL). Mice were challenged with RSV strain A2-line19F, a model of RSV pathogenesis leading to airway mucin expression. Mice were protected against RSV infection and against RSV-induced airway mucin expression and cellular lung inflammation when challenged 6 days after vaccination. Compared to A2-line19F infection alone, TriVax vaccination followed by challenge resulted in effector CD8+ T cells with greater cytokine expression and the more rapid appearance of RSV-specific CD8+ T cells in the lung. When challenged 42 days after TriVax vaccination, memory CD8+ T cells were elicited with RSV-specific tetramer responses equivalent to TriVax-induced effector CD8+ T cells. These memory CD8+ T cells had lower cytokine expression than effector CD8+ T cells, and protection against A2-line19F was partial during the memory phase. We found that vaccine-elicited effector anti-RSV CD8+ T cells protected mice against RSV infection and pathogenesis, and waning protection correlated with reduced CD8+ T cell cytokine expression.

Original languageEnglish (US)
Pages (from-to)13016-13024
Number of pages9
JournalJournal of Virology
Volume86
Issue number23
DOIs
StatePublished - Dec 1 2012

Fingerprint

Respiratory Syncytial Viruses
varespladib methyl
Vaccines
pathogenesis
T-lymphocytes
vaccines
T-Lymphocytes
viruses
mice
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus Infections
Vaccination
vaccination
Mucins
Cytokines
cytokines
mucins
infection
lungs
Immunodominant Epitopes

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Vaccine-elicited CD8+T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. / Lee, Sujin; Stokes, Kate L.; Currier, Michael G.; Sakamoto, Kaori; Lukacs, Nicholas W.; Celis, Esteban; Moore, Martin L.

In: Journal of Virology, Vol. 86, No. 23, 01.12.2012, p. 13016-13024.

Research output: Contribution to journalArticle

Lee, Sujin ; Stokes, Kate L. ; Currier, Michael G. ; Sakamoto, Kaori ; Lukacs, Nicholas W. ; Celis, Esteban ; Moore, Martin L. / Vaccine-elicited CD8+T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice. In: Journal of Virology. 2012 ; Vol. 86, No. 23. pp. 13016-13024.
@article{76e042b4046b4253a5284c704332952c,
title = "Vaccine-elicited CD8+T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice",
abstract = "CD8+ T cells may contribute to vaccines for respiratory syncytial virus (RSV). Compared to CD8+ T cells responding to RSV infection, vaccine-elicited anti-RSV CD8+ T cells are less well defined. We used a peptide vaccine to test the hypothesis that vaccine-elicited RSV-specific CD8+ T cells are protective against RSV pathogenesis. BALB/c mice were treated with a mixture (previously termed TriVax) of an M282-90 peptide representing an immunodominant CD8 epitope, the Toll-like receptor (TLR) agonist poly(I·C), and a costimulatory anti-CD40 antibody. TriVax vaccination induced potent effector anti-RSV CD8+ cytotoxic T lymphocytes (CTL). Mice were challenged with RSV strain A2-line19F, a model of RSV pathogenesis leading to airway mucin expression. Mice were protected against RSV infection and against RSV-induced airway mucin expression and cellular lung inflammation when challenged 6 days after vaccination. Compared to A2-line19F infection alone, TriVax vaccination followed by challenge resulted in effector CD8+ T cells with greater cytokine expression and the more rapid appearance of RSV-specific CD8+ T cells in the lung. When challenged 42 days after TriVax vaccination, memory CD8+ T cells were elicited with RSV-specific tetramer responses equivalent to TriVax-induced effector CD8+ T cells. These memory CD8+ T cells had lower cytokine expression than effector CD8+ T cells, and protection against A2-line19F was partial during the memory phase. We found that vaccine-elicited effector anti-RSV CD8+ T cells protected mice against RSV infection and pathogenesis, and waning protection correlated with reduced CD8+ T cell cytokine expression.",
author = "Sujin Lee and Stokes, {Kate L.} and Currier, {Michael G.} and Kaori Sakamoto and Lukacs, {Nicholas W.} and Esteban Celis and Moore, {Martin L.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1128/JVI.01770-12",
language = "English (US)",
volume = "86",
pages = "13016--13024",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "23",

}

TY - JOUR

T1 - Vaccine-elicited CD8+T cells protect against respiratory syncytial virus strain A2-line19F-induced pathogenesis in BALB/c mice

AU - Lee, Sujin

AU - Stokes, Kate L.

AU - Currier, Michael G.

AU - Sakamoto, Kaori

AU - Lukacs, Nicholas W.

AU - Celis, Esteban

AU - Moore, Martin L.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - CD8+ T cells may contribute to vaccines for respiratory syncytial virus (RSV). Compared to CD8+ T cells responding to RSV infection, vaccine-elicited anti-RSV CD8+ T cells are less well defined. We used a peptide vaccine to test the hypothesis that vaccine-elicited RSV-specific CD8+ T cells are protective against RSV pathogenesis. BALB/c mice were treated with a mixture (previously termed TriVax) of an M282-90 peptide representing an immunodominant CD8 epitope, the Toll-like receptor (TLR) agonist poly(I·C), and a costimulatory anti-CD40 antibody. TriVax vaccination induced potent effector anti-RSV CD8+ cytotoxic T lymphocytes (CTL). Mice were challenged with RSV strain A2-line19F, a model of RSV pathogenesis leading to airway mucin expression. Mice were protected against RSV infection and against RSV-induced airway mucin expression and cellular lung inflammation when challenged 6 days after vaccination. Compared to A2-line19F infection alone, TriVax vaccination followed by challenge resulted in effector CD8+ T cells with greater cytokine expression and the more rapid appearance of RSV-specific CD8+ T cells in the lung. When challenged 42 days after TriVax vaccination, memory CD8+ T cells were elicited with RSV-specific tetramer responses equivalent to TriVax-induced effector CD8+ T cells. These memory CD8+ T cells had lower cytokine expression than effector CD8+ T cells, and protection against A2-line19F was partial during the memory phase. We found that vaccine-elicited effector anti-RSV CD8+ T cells protected mice against RSV infection and pathogenesis, and waning protection correlated with reduced CD8+ T cell cytokine expression.

AB - CD8+ T cells may contribute to vaccines for respiratory syncytial virus (RSV). Compared to CD8+ T cells responding to RSV infection, vaccine-elicited anti-RSV CD8+ T cells are less well defined. We used a peptide vaccine to test the hypothesis that vaccine-elicited RSV-specific CD8+ T cells are protective against RSV pathogenesis. BALB/c mice were treated with a mixture (previously termed TriVax) of an M282-90 peptide representing an immunodominant CD8 epitope, the Toll-like receptor (TLR) agonist poly(I·C), and a costimulatory anti-CD40 antibody. TriVax vaccination induced potent effector anti-RSV CD8+ cytotoxic T lymphocytes (CTL). Mice were challenged with RSV strain A2-line19F, a model of RSV pathogenesis leading to airway mucin expression. Mice were protected against RSV infection and against RSV-induced airway mucin expression and cellular lung inflammation when challenged 6 days after vaccination. Compared to A2-line19F infection alone, TriVax vaccination followed by challenge resulted in effector CD8+ T cells with greater cytokine expression and the more rapid appearance of RSV-specific CD8+ T cells in the lung. When challenged 42 days after TriVax vaccination, memory CD8+ T cells were elicited with RSV-specific tetramer responses equivalent to TriVax-induced effector CD8+ T cells. These memory CD8+ T cells had lower cytokine expression than effector CD8+ T cells, and protection against A2-line19F was partial during the memory phase. We found that vaccine-elicited effector anti-RSV CD8+ T cells protected mice against RSV infection and pathogenesis, and waning protection correlated with reduced CD8+ T cell cytokine expression.

UR - http://www.scopus.com/inward/record.url?scp=84869210900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869210900&partnerID=8YFLogxK

U2 - 10.1128/JVI.01770-12

DO - 10.1128/JVI.01770-12

M3 - Article

VL - 86

SP - 13016

EP - 13024

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 23

ER -